Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, Jordan University of Sciences and Technology (JUST), Irbid, Jordan.
Biochem123, London, NW7 4AU, UK.
J Epidemiol Glob Health. 2023 Jun;13(2):180-190. doi: 10.1007/s44197-023-00096-2. Epub 2023 Apr 24.
The increase in the prevalence of infections caused by certain bacteria, such as Klebsiella pneumonia (K. pneumoniae), is a global health concern. Bacterial production of an enzyme called extended-spectrum beta-lactamase (ESBL) can generate resistance to antimicrobial therapeutics. Therefore, between 2012 and 2013, we investigated K. pneumoniae that produce ESBLs with the prevalence of individual genes including bla, bla, bla, and bla isolated from clinical samples. A total of 99 variable diagnostic samples including blood from hematological malignancies (n = 14) or other clinical sources including sputum, pus, urine, and wound (n = 85) were analyzed. All samples' bacterial type was confirmed and their susceptibility to antimicrobial agents was established. Polymerase chain reaction (PCR) amplification was carried out to ascertain presence of specific genes that included bla, bla, bla, and bla Plasmid DNA profiles were determined to assess significance between resistance to antimicrobial agents and plasmid number. It was found that among non-hematologic malignancy isolates, the highest rate of resistance was 87.9% to imipenem, with lowest rate being 2% to ampicillin. However, in hematologic malignancy isolates, the highest microbial resistance was 92.9% to ampicillin with the lowest rate of resistance at 28.6% to imipenem. Among collected isolates, 45% were ESBL-producers with 50% occurrence in hematologic malignancy individuals that were ESBL-producers. Within ESBL-producing isolates from hematologic malignancy individuals, bla was detected in 100%, bla in 85.7%, and bla and bla at 57.1% and 27.1%, respectively. In addition, bla bla, and bla were found in all non-hematological malignancy individuals with bla detected in 55.5% of samples. Our findings indicate that ESBLs expressing bla and bla genes are significantly prevalent in K. pneumoniae isolates from hematologic malignancy individuals. Plasmid analysis indicated plasmids in isolates collected from hematological malignancy individuals. Furthermore, there was a correlation between resistance to antimicrobial agents and plasmids within two groups analyzed. This study indicates an increase in incidence of K. pneumoniae infections displaying ESBL phenotypes in Jordan.
某些细菌引起的感染患病率增加,如肺炎克雷伯菌(K. pneumoniae),这是一个全球性的健康问题。细菌产生一种称为超广谱β-内酰胺酶(ESBL)的酶会产生对抗生素治疗的耐药性。因此,在 2012 年至 2013 年期间,我们调查了从临床样本中分离出的 bla、bla、bla 和 bla 等单个基因的 ESBL 产生的肺炎克雷伯菌的流行情况。总共分析了 99 个可变诊断样本,包括血液来自血液恶性肿瘤(n=14)或其他临床来源,包括痰、脓液、尿液和伤口(n=85)。所有样本的细菌类型均得到确认,并确定了其对抗生素的敏感性。通过聚合酶链反应(PCR)扩增来确定包括 bla、bla、bla 和 bla 在内的特定基因的存在。质粒 DNA 图谱用于评估抗生素耐药性和质粒数量之间的关系。结果发现,在非血液恶性肿瘤分离株中,对亚胺培南的耐药率最高为 87.9%,最低为 2%的氨苄西林。然而,在血液恶性肿瘤分离株中,对氨苄西林的最高微生物耐药率为 92.9%,对亚胺培南的最低耐药率为 28.6%。在所收集的分离株中,有 45%为 ESBL 产生者,其中 50%发生在血液恶性肿瘤个体中。在血液恶性肿瘤个体中的 ESBL 产生者中,bla 在 100%的分离株中检测到,bla 在 85.7%的分离株中检测到,bla 和 bla 在 57.1%和 27.1%的分离株中检测到。此外,所有非血液恶性肿瘤个体中均发现 bla、bla 和 bla,在 55.5%的样本中检测到 bla。我们的研究结果表明,在血液恶性肿瘤个体中分离的肺炎克雷伯菌中,表达 bla 和 bla 基因的 ESBL 非常普遍。质粒分析表明,从血液恶性肿瘤个体中分离的分离株中存在质粒。此外,在所分析的两组之间,抗生素耐药性和质粒之间存在相关性。本研究表明,约旦的肺炎克雷伯菌感染发病率增加,表现出 ESBL 表型。